scout
News|Videos|June 17, 2024

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME